The Delhi High Court on Friday gave a green signal to pharmaceutical companies Biocon and Mylan to manufacture and sell biosimilar drug Trastuzumab for early breast and metastatic gastric cancer.
The court had earlier allowed them to sell its biosimilar drug for metastatic breast cancer.
Earlier the Delhi High Court had allowed Biocon and Mylan to market their product without any reference to Roche's product or biosimilarity.
As a result, Biocon and Mylan, which were facing a challenge from Roche for sale of the biosimilar drug for three indications-metastatic breast cancer, early breast cancer and gastric cancer-would now be free to sell these drugs.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)